Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Wilker

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Molecular and Cellular Cardiology|September 8, 2004
14-3-3 Proteins--a focus on cancer and human diseaseErik Wilker, Michael B Yaffe
Molecular Cancer Research : MCR|January 4, 2008
Activation of epidermal akt by diverse mouse skin tumor promotersJerry Lu, Okkyung Rho, Erik Wilker, et al.
Molecular Carcinogenesis|August 9, 2005
Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotionErik Wilker, Jerry Lu, Okkyung Rho, et al.
The Journal of Biological Chemistry|April 23, 2004
Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidaseGlenn E Brown, Mary Q Stewart, Sarah A Bissonnette, et al.
Molecular Cell|June 7, 2002
Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2Jiejin Li, Brandi L Williams, Lesley F Haire, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2022
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell DiseasePatricia Schroeder, Keertik Fulzele, Sanjeev Forsyth, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Targeted Oncology|February 24, 2023
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast CancerMaureen Caligiuri, Grace L Williams, Jennifer Castro, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Molecular and Cellular Cardiology|September 8, 2004
14-3-3 Proteins--a focus on cancer and human diseaseErik Wilker, Michael B Yaffe
Molecular Cancer Research : MCR|January 4, 2008
Activation of epidermal akt by diverse mouse skin tumor promotersJerry Lu, Okkyung Rho, Erik Wilker, et al.
Molecular Carcinogenesis|August 9, 2005
Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotionErik Wilker, Jerry Lu, Okkyung Rho, et al.
The Journal of Biological Chemistry|April 23, 2004
Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidaseGlenn E Brown, Mary Q Stewart, Sarah A Bissonnette, et al.
Molecular Cell|June 7, 2002
Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2Jiejin Li, Brandi L Williams, Lesley F Haire, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2022
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell DiseasePatricia Schroeder, Keertik Fulzele, Sanjeev Forsyth, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Targeted Oncology|February 24, 2023
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast CancerMaureen Caligiuri, Grace L Williams, Jennifer Castro, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Pageof 2